Tobin Schilke - Jan 9, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Jan 9, 2023
Transactions value $
-$100,525
Form type
4
Date filed
1/10/2023, 07:06 PM
Previous filing
Jan 3, 2023
Next filing
Jan 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale -$42.5K -1.7K -2.72% $25.00 60.9K Jan 9, 2023 Direct F1
transaction RVNC Common Stock Sale -$28K -1K -1.64% $28.00 59.9K Jan 9, 2023 Direct F1
transaction RVNC Common Stock Sale -$30K -1K -1.67% $30.00 58.9K Jan 9, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.